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comparison was applied to compare entecavir with interferon and the combination of 
interferon and lamivudine. When compared with lamivudine, the combination of inter-
feron and lamivudine yielded the best efﬁ cacy which was about two times more likely to 
increase HBeAg seroconversion rate (OR = 2.38, 95% CI = 1.21–4.06) than entecavir 
(OR = 0.98, 95% CI = 0.56–1.44) and interferon (OR = 1.17, 95% CI = 0.44–2.24). In 
addition, when compared with either interferon or entecavir, interferon plus lamivudine 
was about two to three times more likely to enhance HBeAg seroconversion rate with the 
OR of 2.48 (95% CI = 1.05–4.92) or 2.71 (95% CI = 1.13–5.33), respectively. CONCLU-
SIONS: There was a signiﬁ cant increase in HBeAg seroconversion rate in patients with 
HBeAg positive CHB receiving the combination of interferon and lamivudine com-
pared with lamivudine, entecavir and interferon. 
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OBJECTIVES: To evaluate clinical outcome and direct medical cost using Kabiven 
and traditional peripheral partenteral nutrition for postoperative patients in ICU. 
METHODS: This is a restrospective study. Medical records of postoperative patients 
in ICU were reviewed by clinical pharmacists from July 2008 to July 2009. The 
retrieved patients were divided into two groups, kabiven group (n = 49) and separate 
bottle group (SB) (n = 50). Patients, characteristics were evaluated and compared 
between two groups. The measured outcomes were the clinical effectiveness and direct 
medical costs. One way ANOVA were used for analysis. RESULTS: There were no 
statistically signiﬁ cance difference in patients, characteristics between two groups. 
Survival rate was higher in kabiven group than in SB group (40% vs. 31%, respec-
tively). The length of stay in hospital in kabiven group was longer than in SB group 
(47.51 ± 38.63 vs. 31.86 ± 21.99 days, respectively; P < 0.015). Total direct medical 
costs of survivors in kabiven group was more expensive than in SB group ($11,976.9 
vs. $9574.9, respectively). CONCLUSIONS: Although the direct medical cost of 
kabiven group were higher than SB group, use of kabiven is likely to improve mortality 
rate of postoperative patients in ICU. 
GASTROINTESTINAL DISORDERS – Cost Studies
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OBJECTIVES: Heptatitis B is prevalent in South Korea and chronic hepatitis B (CHB) 
infection is an important public health issue due to its potential to evolve to cirrhosis, 
hepatocellular carcinoma. This study estimated the direct medical cost of CHB-related 
disease states in South Korea and compared the cost of South Korea with that of USA, 
Australia and China. It also aimed to analyze the impact of three therapeutic alterna-
tives for CHB by Budget Impact Analysis (BIA). METHODS: Dynamic budget impact 
analysis was conducted based on a Markov model for 5 years. Three treatment sce-
narios were selected as follows: ﬁ rst-line treatment of lamivudine, second-line combi-
nation treatment of lamivudine and adefovir on the development of drug resistance, 
ﬁ rst-line treatment of lamivudine, second-line treatment of entecavir 1.0 mg on the 
development of drug resistance, ﬁ rst-line treatment of entecavir 0.5 mg, second-line 
treatment of adefovir on the development of drug resistance, no treatment available. 
RESULTS: The BIA results of scenario A, B, C and no treatment were 75, 74.7, 85.9, 
and 48.1 billion Korean Won (KRW), respectively. The results were relatively insensi-
tive to the TP and sensitive to the number of treated patients based on sensitivity 
analyses. The costs of annual direct medical costs in South Korea were 23.2%~65.8%, 
16.2%~59.1%, and 75.8%~381.7% of the annual direct medical costs in the United 
States, Australia, and China. CONCLUSIONS: Scenario C (ﬁ rst-line treatment of 
entecavir 0.5 mg, second-line treatment of adefovir) was found to be 10.9~11.2 billion 
KRW more expensive than scenario A and B from payer’s perspective. In South Korea, 
the direct medical costs of CHB-related diseases are cheaper than the United States 
and Australia. It suggests that such factors as the difference of GNP (Gross National 
Product), health-care system and others contribute to the difference of the direct 
medical costs. 
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OBJECTIVES: Our objective was to compare cost saving before and after of pharma-
ceutical care implementation and Octreotide use evaluation at surgical ward. 
METHODS: This study was conducted during October 1, 2008 to April 30, 2009. The 
research instruments were octreotide use criteria with approval by surgical staffs. Phar-
macist reviewed and evaluated the medical chart in order to identify medication related 
problems by focusing on medication regimens. Medication related problems were clas-
siﬁ ed into three categories: inappropriate route, inappropriate duration and inappropri-
ate indication of administration. Cost saving was based on drug costs. The pre- and 
post-pharmaceutical care implementation and octreotide use evaluation results were 
compared and analyzed with descriptive retrospective statistics and paired t–test at 95 
% signiﬁ cant level. RESULTS: There were 302 patients received Octreotide. One 
hundred ninety-three patients (63.9%) were prescribed Octreotide appropriately. Medi-
cation related problems were found in 109 patients (36.1%). The most frequent prob-
lems were inappropriate duration (44.95%), inappropriate indication (34.86%) and 
inappropriate route of administration (20.18%). The cost of Octreotide use for inap-
propriate duration, inappropriate indication and inappropriate route of administration 
were signiﬁ cantly decreased after pharmaceutical care implementation 3,062,160 versus 
1,946,400 baht, 657,000 versus no money, and 919,800 versus 226,800 baht, respec-
tively (P < 0.005). The total cost of Octreotide use was 9,529,950 baht reducing to 
7,015,008 baht after pharmaceutical care implementation with statistically signiﬁ cant 
(P < 0.005). CONCLUSIONS: The implementation of pharmaceutical care and evalu-
ation of Octreotide use resulted in signiﬁ cant cost saving. The drug utilization 
program, consisting of deriving quality criteria for prescribing, structured order form 
and good cooperation between physicians and pharmacists with strong support of the 
therapeutics committee, was an effective strategic approach to promote rational drug 
use and develop Octreotide use guidelines. 
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OBJECTIVES: Chronic viral hepatitis B and C are treated primarily with interferon 
(IFN) and/or nucleotide analogs e.g., ribavirin (RBV) which produced sustained viral 
response in more than 50% of treated patients. However, the combination may also 
cause numerous side effects that could reduce patients’ quality of life (QoL). To 
determine the effect of antiviral therapy on QoL of chronic hepatitis patients. 
METHODS: Key words were “Quality of life” AND “chronic hepatitis” AND “anti-
viral therapy,” “lamivudine,” “ribavirin,” “adefovir,” “entacavir,” “telbivudine” 
“tenofovir” and were searched from PubMed and EMBASE database. Study selection 
criteria were original articles in which patients received antivirals for chronic hepatitis 
B or C, and assessed QoL. The comparators were no treatment, placebo or at least 
one other antiviral. Studies that involved co-HIV infection were excluded. One inde-
pendent researcher reviewed titles and abstracts to determine relevance. Study design, 
dose, duration, baseline values, and QoL scores were extracted. RESULTS: Six studies 
met all the criteria. Four QoL instruments were used in those studies. SF 36 and 
HQLQ questionnaires were the most common. Patients who received peginterferonμ-
2a plus placebo reported better QoL than peginterferonμ-2a plus ribavirin during the 
treatment (week 2–48) in two RCTs. However, the results were less consistent and 
less prominent during the week of 72 and 96. The effect seemed to be non-dose related. 
One RCT showed that interferon μ plus ribavirin produced better QoL than untreated 
when measured with EQ 5D questionnaire, but it did not reach statistical signiﬁ cant. 
In similarly, peginterferone μ-2a plus ribavirin did not showed a signiﬁ cant better 
Fatigue severity scale at week 72 when compared with peginterferonμ-2a plus placebo. 
CONCLUSIONS: Antiviral therapy (interferon plus ribavirin) reduced QoL only 
during the treatment. Results seemed to be consistent across all four types of QoL 
questionnaires. 
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OBJECTIVES: This study was conducted to obtain information on current prescribing 
rates of antibiotics in diarrhea, a condition where misuse of antibiotics is common. 
In the absence of community-based databases on antibiotic use in developing countries 
recently a methodology was established for surveillance of antibiotic use at New Delhi 
by conducting ‘Exit Interviews’ of the patients. METHODS: Antibiotic use data was 
collected from public and private sector facilities from four residential localities 
around a tertiary care hospital where the antibiotic resistance work was being con-
ducted. All the 10 public sector facilities (eight primary and two secondary health 
cares) situated in the study area under Delhi government were enrolled. For private 
sector, 20 willing and cooperative general practitioners and specialists practicing in 
the chosen areas were selected. Patients after consultation with prescriber were asked 
if they had diarrhea but without blood. Patients with diarrhea were enrolled for exit 
interview and his/her prescription was monitored. Antibiotic use data was collected 
per month over 1 year (December 2007–November 2008). The percentage of patients 
receiving antibiotic and pattern of consumption for various antibiotics was analyzed. 
RESULTS: At public facilities 43% (171/398) and at private facilities 69% (76/110) 
of patients with diarrhea were prescribed at least one antibiotic. Main antibiotic class 
that was prescribed in public and private sector was ﬂ uoroquinolones (89% and 94%); 
